Phase III study of Efficacy, Safety and Pharmacokinetics of SJP-0129 in the Treatment for Patent Ductus Arteriosus
Phase of Trial: Phase III
Latest Information Update: 29 Jul 2016
At a glance
- Drugs SJP 0129 (Primary)
- Indications Patent ductus arteriosus
- Focus Therapeutic Use
- Sponsors Senju Pharmaceutical
- 28 Jul 2016 Status changed from active, no longer recruiting to completed.
- 07 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan record.